Skip to main content

LABU

ETF
—
—

Performance overview

LABU Price
Price Chart

Forward-looking statistics

Beta
2.91
Risk
73.49%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Fund info

The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards ("GICS"). The fund is non-diversified.

Investing methodPassively Managed
DiversifiedNo
Expense ratio1.04%
Asset classUnknown

Company info

Sector—
Industry—
Website—
AUM—

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$0.21
Revenue per share—
Avg trading volume (30 day)$109M
Avg trading volume (10 day)$84M
Put-call ratioN/A

Macro factor sensitivity

Growth+1.8
Credit+15.3
Liquidity+0.5
Inflation-8.0
Commodities-1.0
Interest Rates-4.8

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 25, 2025

News

Best Inverse/Leveraged ETFs of Last Week

Wall Street offered a mixed performance last week.

Zacks Investment Research (July 30, 2024)
A Biotech ETF For Aggressive, Risk-Tolerant Investors

The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer's Disease.

Benzinga (June 8, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free